Brookline upgraded Oncternal Therapeutics to Buy from Hold with a $2 price target, citing upcoming data.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ONCT:
- Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
- ONCT Earnings this Week: How Will it Perform?
- Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
- Oncternal Therapeutics announces Fast Track designation for ONCT-534
- Oncternal Therapeutics appoints Matthew Smith to Prostate Cancer SAB